Exscientia to receive up to CHF67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche
Exscientia – the world-leading artificial intelligence (AI)-driven drug discovery company — is pleased to announce a drug discovery collaboration with Roche.
Exscientia will apply its cutting-edge, Centaur Chemist, AI drug discovery platform to design preclinical drug candidates for Roche. Roche has the exclusive rights to develop and market the drug candidates resulting from the collaboration.
Exscientia receives upfront and research funding as well as preclinical, development and commercial milestone payments.
Together, the combined financial reward is worth up to CHF67 million to Exscientia, plus tiered royalties on the annual net sales of any products resulting from the collaboration. No further financial details are disclosed.
Andrew Hopkins, CEO of Exscientia, said: "The application of AI into early stage drug discovery has the potential to offer transformational benefits in terms of productivity and quality to the generation of new medicines."
"Increasingly, we are seeing in our own pipeline projects and with our ongoing collaborations, the success of our AI platform in drug discovery. This new partnership with Roche demonstrates the value of our AI-driven platform and its potential to deliver high value assets. We are very pleased to begin this exciting project with such a respected partner.”